Boston, Massachusetts 02215


The purpose of this protocol is to conduct a pilot study to investigate whether pancreatic enzyme supplementation will improve symptoms in individuals with celiac disease who suffer persistent symptoms despite a gluten free diet. This protocol specifically aims to: 1. Evaluate the efficacy of pancreatic enzyme supplementation for reduction of gastrointestinal symptoms in patients with celiac disease on a gluten free diet. 2. Assess the ability of fecal elastase levels to predict response to pancreatic enzyme supplementation in patients with celiac disease on a gluten free diet.


Inclusion Criteria: - Biopsy proven celiac disease. - Age 18-80. - Ongoing symptoms defined as a CeD-GSRS score of greater than 3 during the run in period. - Subject must be following a gluten free diet. - tTG < 40 units at screening. Exclusion Criteria: - Taking prescription or over the counter enzyme supplements for 1 month prior to enrollment. - Pregnant, breastfeeding or planning pregnancy. Woman using acceptable methods of contraception will be included. Acceptable methods of contraception include oral hormonal contraceptives, implanted hormonal contraceptives, diaphragm with spermicide, condoms, intra-uterine device, abstinence, and male partner vasectomy. - Patients with a pork allergy or who are unwilling to consume pork products. - English proficiency unsuitable for completion of surveys. - Known severe pancreatic disease. - Known history of prior cancer (except squamous or basal cell skin cancer). - Patients with lactose intolerance who are unable to tolerate a minimum of 1oz (2 tablespoons) of whole milk per day. - Clinically significant abnormality in safety lab values (i.e. CBC and BMP) at screening that may impact subject safety or the scientific integrity of the study. - Other known active GI condition including but not limited to inflammatory bowel disease, small intestine bacterial overgrowth, and obvious FODMAP intolerance. - History of all major gastrointestinal surgery other than appendectomy or cholecystectomy. - Comorbid condition that in the opinion of the investigator would interfere with the subject's participation in the study or would confound the results of the study.



Primary Contact:

Principal Investigator
Ciaran Kelly, MD
Beth Israel Deaconess Medical Center

Sarah Madoff, BS
Phone: 617-667-8266

Backup Contact:


Location Contact:

Boston, Massachusetts 02215
United States

Sarah Madoff, BS
Phone: 617-667-8266

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.